1 report

  • May 15, 2018: Zosano Pharma Announces First Quarter 2018 Financial Results
  • Jan 05, 2017: Zosano Pharma Announces Last Subject Treated in its Migraine Pivotal Trial

These symptoms include photophobia, A key secondary endpoint of this trial is pain relief at ## min, aimed at demonstrating the rapid relief profile of M##.

  • Pain Relief
  • Pharmaceutical
  • United States
  • Company
  • Zosano Pharma Corporation